Oppel T, Pavicic T, Kamann S, Bräutigam M, Wollenberg A
Department of Dermatology and Allergy, Ludwig-Maximilians University, Munich, Germany.
J Eur Acad Dermatol Venereol. 2007 Oct;21(9):1175-80. doi: 10.1111/j.1468-3083.2007.02191.x.
Perioral dermatitis (POD) is a common skin disease and difficult to treat. Pimecrolimus cream (1%) successfully controls atopic eczema.
Our aim was to investigate its efficacy in POD.
Single-centre, randomized, double-blind, vehicle-controlled study including 40 POD patients with a 4-week treatment and a 4-week follow-up. Efficacy was assessed by a novel Perioral Dermatitis Severity Index (PODSI) and Finlay's Dermatology Life Quality Index (DLQI).
Outpatient clinics of a large dermatological hospital in Munich, Germany.
During treatment, the PODSI was significantly lower in the pimecrolimus group compared with vehicle (P = 0.005-0.02) whereas at follow-up, no significant differences were observed. At week 2, the responder rates (> or = 50% PODSI improvement) were 50% with pimecrolimus cream (1%) and 25% with vehicle (P = 0.095). DLQI was improved in pimecrolimus group compared with vehicle.
Results suggest that pimecrolimus cream (1%) effectively treats acute-stage POD.
口周皮炎（POD）是一种常见的皮肤病且难以治疗。1%吡美莫司乳膏可成功控制特应性皮炎。
我们的目的是研究其对口周皮炎的疗效。
单中心、随机、双盲、赋形剂对照研究，纳入40例口周皮炎患者，进行为期4周的治疗和4周的随访。通过一种新的口周皮炎严重程度指数（PODSI）和芬利皮肤病生活质量指数（DLQI）评估疗效。
德国慕尼黑一家大型皮肤病医院的门诊。
治疗期间，吡美莫司组的PODSI显著低于赋形剂组（P = 0.005 - 0.02），而在随访时，未观察到显著差异。在第2周时，1%吡美莫司乳膏组的缓解率（PODSI改善≥50%）为50%，赋形剂组为25%（P = 0.095）。与赋形剂组相比，吡美莫司组的DLQI有所改善。
结果表明，1%吡美莫司乳膏可有效治疗急性期口周皮炎。
